Novartis Partnering

A female scientist in a laboratory

Innovation through collaborations

Our Mission

Welcome to Global Business Development and Licensing (BD&L) and Mergers and Acquisition (M&A) at Novartis

Within BD&L our mission is:

  • To create long term collaborations

    to access therapeutic products, technology platforms and break through innovations with the potential to reimagine medicine, to ease suffering and to enhance the quality of life.

  • To create long term shareholder value

    by refocusing our pipeline to the strategic priorities through divestments of assets.

  • To build a wide network within the life science community

    to have access to new innovation and to explore opportunities in our core strategic areas as well as outside which have the potential to set our future direction.

 

Our Leadership
“We are working with Novartis partners to shape the future of innovation”
Nigel Sheail Global Head M&A and BD&L

Novartis and Microsoft AI collaboration

Novartis and Microsoft announced their collaboration to transform medicine with artificial intelligence

Read More

Key Therapeutic Areas and focus

  • Image generated using machine learning

    Disease Areas

    Cardiovascular, Renal and Metabolism, Hepatology, Immunology & Dermatology, and Renal, Neuroscience, Respiratory, Ophthalmology & ENT, Musculoskeletal Diseases, Renal / Nephrology

  • Group of business people in a meeting

    Platforms and Technologies

    Cell & Gene Therapy, Digital, Precision Medicine – Diagnostic Technologies, Biologics, Chemistry & Chemical Biology

  • Image of a simplified brain

    Sandoz

    Small Molecules & Generics, Biopharmaceuticals

  • Hands with gloves manipulating products in a lab

    Other Divisions & Functions

    M&A, Venture Investments, Alliance Management,Out-licensing and Divestments

Contact Us

Download the partnering contact sheet (PDF 0.2 MB)

For direct submissions of project proposals please use the following link

Events